Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives. The Food and Drug Administration approved Roche's blockbuster Avastin in 2008 based on early-stage trials after it was seen that it shrank tumors caused by breast cancer. The decision was controversial because drugs for cancer patients who have ...